Using the same methodology we also examined the associations of other lipid-lowering drug targets, including PCSK9 (proprotein convertase subtilisin/kexin type 9; target of PCSK9 inhibitors) and NPC1L1 (NPC1 like intracellular cholesterol transporter 1; target of ezetimibe), and LDL cholesterol-lowering effects with the risk of ankylosing spondylitis. This evidence concerns the gene PCSK9 and ankylosing spondylitis.